Intra-Cellular Therapies, Inc.
NOVEL USES

Abstract:

The disclosure provides methods, treatments and materials for enhancing the effect of an adenosine A.sub.2 receptor agonist in the treatment, mitigation or prophylaxis of a disease or condition characterized by inotropic and/or lusitropic dysfunction, and/or enhancing adenosine A.sub.2 receptor function in the treatment, mitigation or prophylaxis of a disease or condition characterized by impaired adenosine A.sub.2 receptor function, comprising administration of an effective amount of a PDE1 inhibitor to a patient in need thereof, for example a patient suffering from heart failure.